Synthesis and antiproliferative activities of ottelione a analogues - Test2 - elhamkhani - TriplyDB

Synthesis and antiproliferative activities of ottelione a analogues

Synthesis and antiproliferative activities of ottelione a analogues

http://www.wikidata.org/entity/Q33630497

about

New diarylheptanoids and a hydroxylated ottelione from Ottelia alismoides Therapeutic effects of the euglenoid ichthyotoxin, euglenophycin, in colon cancer.Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.

P2860

Q36501324-5CDC254F-A347-423C-8150-7EC4F696A2D0 Q47126863-6E2C2E1A-F0E0-4FB8-ACFE-A9837DE3820F Q47773650-ADFD4FDE-7526-4003-962C-0CEB4A38AFD6

P2860

Synthesis and antiproliferative activities of ottelione a analogues

http://www.wikidata.org/entity/Q33630497

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Synthesis and antiproliferative activities of ottelione a analogues

@ast

Synthesis and antiproliferative activities of ottelione a analogues

@en

type

label

Synthesis and antiproliferative activities of ottelione a analogues

@ast

Synthesis and antiproliferative activities of ottelione a analogues

@en

prefLabel

Synthesis and antiproliferative activities of ottelione a analogues

@ast

Synthesis and antiproliferative activities of ottelione a analogues

@en

P1433

Q33630497-6B8FFA72-D11A-46B4-B30E-DC695742A74E

P1476

Q33630497-FCC9D73F-68B9-4128-BA18-2DACFEE43083

P2093

Q33630497-00ED85A5-2E61-43E4-AA05-A183CEE9E41F

Q33630497-0C2C4079-3AC3-4CE5-A5A6-370F125CD09E

Q33630497-2629ACA6-84E7-4A0C-862B-5F43FF32B6B6

Q33630497-35673504-1ADB-4DE6-B708-09112305A528

Q33630497-54032A68-5FDB-460B-AD0A-645B05E315D1

Q33630497-767A7E0B-5723-4503-93D6-29BCA0B6D241

Q33630497-A575FFDB-80AF-4411-8FF1-D4BF379A2B27

Q33630497-E9D7B85E-8DED-4A75-9DCB-A712F5079916

P2860

Q33630497-06FF2FD5-B5B1-40D3-8665-0953D4F5AF91

Q33630497-1243C7D7-D4F0-46A9-95D9-CCD10E4B8A8F

Q33630497-2E0B36CC-E942-41C5-97F2-ADED29C4C13F

Q33630497-3FC91B95-80DF-4A04-BBD2-0F4741C02563

Q33630497-5E07AE72-C415-407F-A0E0-D979539ED915

Q33630497-67EC6A2C-1973-4EAB-B1CC-63FCCD14ABB8

Q33630497-71C001CE-1BAA-4F09-AA75-8A640C57E941

Q33630497-7F24468F-7BDD-4D01-9326-F1D0E0D572CA

Q33630497-8E990D1D-C160-45AC-A690-BBEA9EE9B01C

Q33630497-A17A3E98-FA90-4125-A24D-D2FAE76AD744

P304

Q33630497-7E3F24E4-868D-443C-8B5B-E2E42159431E

P31

Q33630497-F081921C-8B9F-4A46-BFCC-12144D8E0828

P356

Q33630497-C5422DA6-1164-413E-91CF-DC396230042A

P433

Q33630497-988110A9-89A3-458A-8789-0662E54E0D2F

P478

Q33630497-1AA5963E-9142-4153-BB7F-958DC863029C

P577

Q33630497-C378FB96-C3F3-4227-91C9-11778DABBDA7

P698

Q33630497-79C336AD-E5A2-41E6-9288-49E8C998789E

P932

Q33630497-0798B3CD-09F8-4E5A-B9EF-75838E63E59E

P356

P1433

ACS Medicinal Chemistry Letters

P1476

Synthesis and antiproliferative activities of ottelione a analogues

@en

P2093

Chih-Shang Chen

http://www.w3.org/2001/XMLSchema#string

Chin-Kang Sha

http://www.w3.org/2001/XMLSchema#string

Hsiang Yu Chen

http://www.w3.org/2001/XMLSchema#string

Jiann-Jyh Huang

http://www.w3.org/2001/XMLSchema#string

Tsai-Yuan Chang

http://www.w3.org/2001/XMLSchema#string

Win-Yin Wei

http://www.w3.org/2001/XMLSchema#string

Ying-Shuan E Lee

http://www.w3.org/2001/XMLSchema#string

Yun-Peng Tu

http://www.w3.org/2001/XMLSchema#string

P2860

Tubulin-interactive natural products as anticancer agents

Irreversible inhibitors of serine, cysteine, and threonine proteases

Microtubules as a target for anticancer drugs

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

RPR112378 and RPR115781: two representatives of a new family of microtubule assembly inhibitors.

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.

Recent development and SAR analysis of colchicine binding site inhibitors.

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors

Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.

AVE8062: a new combretastatin derivative vascular disrupting agent.

P304

1075-1080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ML300283F

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24900431

http://www.w3.org/2001/XMLSchema#string

P932

4025792

http://www.w3.org/2001/XMLSchema#string